NYSE moves to bring all-or-nothing options to stocks and company earnings. The ​lineup includes 12 underlying securities, including $AAPL, $NVDA, $TSLA, and $SPY with additional securities to be added over time reuters.com/legal/government…

$NVO Loses US Court Ruling to Block $LLY Weight-Loss Drug Ads reuters.com/world/us-judge-l…

Yeppp. Its over 😬

$ZURA TibuSHIELD topline data in hidradenitis suppurativa remains on track for Q4 TibuSURE topline data in systemic sclerosis (SSc) remains on track for 1H'27; enrollment completed with 91 participants randomized, exceeding target Cash and cash equivalents of $187.7M

$ARTV The decision follows the review of the overall risk-benefit in the context of updated clinical data, including longer-term follow-up, and two Grade 5 safety events

$ARTV Announces Strategic Update and Discontinues Development of AlloNK. 94% workforce reduction globenewswire.com/news-relea…

$ARTV halt

$XNCR PT raised to $43 at RBC

$PFE Phase 3 MagnetisMM-32 trial ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Relapsed or Refractory Multiple Myeloma businesswire.com/news/home/2…

$BEAM Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) investors.beamtx.com/news-re…

$EQ First Subject Dosed in Phase 1 Trial of EQ504 Topline Phase 1 data anticipated in Q2'27 Triggers Milestone Closing of $20M. Co to sell 14.95M shares at $0.57/share and 20M pre-funded warrants at $0.56/per warrant

$MIRM Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva businesswire.com/news/home/2…

$CORT Reports Positive Results from Phase 2 BELLA Trial of Lifyorli Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer businesswire.com/news/home/2…

$MRNA PT raised to $230 from $167 at Piper

$ORKA CC at 8 am to report Wk 16 data for ORKA-001 from the ongoing EVERLAST-B trial on Monday

$SMMT Ivonescimab Plus Chemotherapy Demonstrates OS Superiority Compared to Durvalumab Plus Chemo in Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study. #ESMO26 Ivonescimab Plus Chemotherapy Reduced the Risk of Death by 25% Compared to Durvalumab Plus Chemotherapy; OS Hazard Ratio 0.75 businesswire.com/news/home/2…

$GMAB Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful ORR in Patients with Metastatic Colorectal Cancer. #ESMO26 businesswire.com/news/home/2…

$AGEN Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at #ESMO26 businesswire.com/news/home/2…

$MRNA Investors Should Brace for More Whiplash Even after its sharp fall, the drugmaker’s stock price assumes wild successes wsj.com/health/pharma/modern…

$ZYME Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at #ESMO26 cORR of 64.5% at the 6.4 mg/kg dose in patients with high-grade serous platinum-resistant ovarian cancer ir.zymeworks.com/news-releas…